NCT00332371

Brief Summary

The study objective is to clarify whether the application of CPFA (coupled plasma-filtration adsorption) in addition to the current clinical practice is able to reduce mortality and prevent organ failures in septic shock patients in intensive care unit (ICU).

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
184

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Dec 2006

Longer than P75 for not_applicable

Geographic Reach
1 country

19 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 31, 2006

Completed
1 day until next milestone

First Posted

Study publicly available on registry

June 1, 2006

Completed
6 months until next milestone

Study Start

First participant enrolled

December 1, 2006

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2010

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2011

Completed
Last Updated

July 9, 2012

Status Verified

July 1, 2012

Enrollment Period

4 years

First QC Date

May 31, 2006

Last Update Submit

July 5, 2012

Conditions

Keywords

Intensive CareShock, SepticAdsorptionSorption Detoxification

Outcome Measures

Primary Outcomes (1)

  • Hospital mortality (for patients discharged to other hospital, it will be intended as mortality at the discharge from the latest hospital in which the patients stayed)

    At the discharge from the latest hospital

Secondary Outcomes (3)

  • Mortality within 90 days from randomization

    90 days from randomization

  • New organ failures (assessed through SOFA score)

    Within ICU stay

  • Days not spent in the ICU during the first 30 days from randomization

    30 days from randomization

Study Arms (2)

1

EXPERIMENTAL
Device: CPFA (Coupled Plasma Filtration Adsorption)

2

NO INTERVENTION

Interventions

CPFA is a specific method for the treatment of sepsis. It consists of: 1. a plasma-filter (polyethersulfone 0.45 m2 with a cutoff of approx 800 kDa) 2. a hemofilter (polyethersulfone 1,4 m2) 3. a cartridge (contains approximately 140 ml of hydrophobic styrenic resin) The kit is lodged in the Bellco "Lynda" machine (Bellco Mirandola, Italy). The treatment consists of the separation of plasma from the whole blood with adsorption of the inflammatory mediators and cytokines from the plasma, and a subsequent purification step by way of a hemofilter.

Also known as: Coupled Plasma Filtration Adsorption
1

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • All patients admitted to the ICU in septic shock
  • All patients that develop septic shock while in the ICU

You may not qualify if:

  • Age less than 18 years
  • Pregnancy
  • Cardiopulmonary resuscitation
  • Cerebral coma
  • Metastatic cancer
  • Presence of relative or absolute contraindications to CPFA
  • Estimated life expectancy less than 2 weeks
  • Already included in the study
  • Admission from an other ICU where the patient remained for more than 24 hours
  • Absence of informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (19)

Ospedale SS. Antonio e Biagio e C. Arrigo

Alessandria, AL, 15100, Italy

Location

Ospedale Regionale della Valle d'Aosta, Servizio Anestesia e Rianimazione

Aosta, AO, 11100, Italy

Location

Ospedali Riuniti, I Servizio Anestesia e Rianimazione

Bergamo, BG, 24128, Italy

Location

Ospedale Policlinico San Pietro, Servizio Anestesia e Rianimazione

Ponte San Pietro, BG, 24036, Italy

Location

Ospedale Policlinico San Marco, Terapia Intensiva

Zingonia, BG, 24040, Italy

Location

Ospedale Spedali Civili, II Servizio di Anestesia e Rianimazione

Brescia, BS, 25125, Italy

Location

Ospedale Vittorio Emanuele, II Servizio di Anestesia e Rianimazione

Catania, CT, 95100, Italy

Location

Ospedale Morgagni-Pierantoni, U.O. Anestesia e Rianimazione

Forlì, FC, 47100, Italy

Location

Ospedale Careggi - Villa Monna Tessa, TI Polifunzionale e Post-trapianto

Florence, FI, 50134, Italy

Location

Ospedale S. Giovanni di Dio ASL 10, Servizio Anestesia e Rianimazione

Florence, FI, 50143, Italy

Location

Ospedale Civile

Imperia, IM, 18100, Italy

Location

Ospedale Civile, Servizio Anestesia e Rianimazione

Sanremo, IM, 18038, Italy

Location

Ospedale A. Manzoni, U.O. Anestesia e Rianimazione 1

Lecco, LC, 23900, Italy

Location

Ospedale Madonna delle Grazie, U.O. Anestesia e Rianimazione

Matera, MT, 75100, Italy

Location

Ospedale di S. Chiara, VI U.O. di Anestesia, Rianimazione e Pronto Soccorso

Pisa, PI, 56100, Italy

Location

European Hospital

Roma, RM, 00149, Italy

Location

Ospedale San Camillo Forlanini

Roma, RM, 00152, Italy

Location

Ospedale Civile Regione Piemonte ASL 9, Servizio Anestesia e Rianimazione

Ivrea, TO, 10015, Italy

Location

Ospedale San Giovanni Bosco, Servizio Anestesia e Rianimazione B-DEA

Torino, TO, 10148, Italy

Location

Related Publications (1)

  • Livigni S, Bertolini G, Rossi C, Ferrari F, Giardino M, Pozzato M, Remuzzi G; GiViTI: Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva (Italian Group for the Evaluation of Interventions in Intensive Care Medicine) is an independent collaboration network of Italian Intensive Care units. Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: a multicenter randomised controlled clinical trial. BMJ Open. 2014 Jan 8;4(1):e003536. doi: 10.1136/bmjopen-2013-003536.

Related Links

MeSH Terms

Conditions

Shock, Septic

Condition Hierarchy (Ancestors)

SepsisInfectionsSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and SymptomsShock

Study Officials

  • Sergio Livigni, MD

    Ospedale San Giovanni Bosco, Torino, ITALY

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 31, 2006

First Posted

June 1, 2006

Study Start

December 1, 2006

Primary Completion

December 1, 2010

Study Completion

July 1, 2011

Last Updated

July 9, 2012

Record last verified: 2012-07

Locations